Skip to content
  • About Us
    • Management
    • Board of Directors
    • Clinical and Scientific Advisory Board
  • Careers
  • Lead Technology
  • Publications
  • Investors
  • Contact Us
Menu
  • About Us
    • Management
    • Board of Directors
    • Clinical and Scientific Advisory Board
  • Careers
  • Lead Technology
  • Publications
  • Investors
  • Contact Us
Search
Close
36th Annual JPM Healthcare Conference

36th Annual JPM Healthcare Conference

  • Post author:gtmrick
  • Post published:December 25, 2017
  • Post category:Uncategorized

In 2018 Vasomune Therapeutics will be at the 36TH ANNUAL JPM HEALTHCARE CONFERENCE, San Francisco, California

Continue Reading 36th Annual JPM Healthcare Conference
A New Flu Drug Works Astoundingly Well—By Not Targeting the Flu at All

A New Flu Drug Works Astoundingly Well—By Not Targeting the Flu at All

  • Post author:gtmrick
  • Post published:June 13, 2015
  • Post category:Uncategorized

A New Flu Drug Works Astoundingly Well—By Not Targeting the Flu at All. Continue reading at Motherboard Vice.

Continue Reading A New Flu Drug Works Astoundingly Well—By Not Targeting the Flu at All
Preventing the flu: Researchers looking for a new approach

Preventing the flu: Researchers looking for a new approach

  • Post author:gtmrick
  • Post published:June 5, 2015
  • Post category:Uncategorized

Lifetime: New approach to fighting influenza Advertise on CTVNews.ca

Continue Reading Preventing the flu: Researchers looking for a new approach
  • Go to the previous page
  • 1
  • 2

Recent Posts

  • Vasomune Announces Initiation of the First-in-Human Clinical Trial of a Potential Vascular Normalization COVID-19 Treatment
  • Vasomune Announces FDA Allowance of IND Application for AV-001 for the Treatment of Hospitalized Patients with COVID-19
  • Learn More About Vasomune’s Partnership with University of Iowa Pharmaceuticals’ COVID-19 Drug Manufacturing
  • Vasomune Receives a US $2.8 Million PRMRP Grant from the US Department of Defense to Develop AV-001 for the Treatment of ALI/ARDS of Any Cause, Including COVID-19
  • Vasomune Therapeutics Announces Clinical and Scientific Advisory Board

Recent Comments

    Archives

    • December 2020
    • November 2020
    • August 2020
    • May 2020
    • March 2020
    • February 2020
    • January 2020
    • August 2018
    • December 2017
    • June 2015

    Categories

    • Press Release
    • Uncategorized

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    About

    Vasomune Therapeutics is a private biotechnology company developing the next generation of medications to harness the body’s ability to defend against illness by modifying cellular response to disease.

    Vasomune Therapeutics 2020 © All Rights Reserved.